Abstract:11 Background: Penile squamous cell carcinoma (SCC) is an extremely rare, aggressive disease, representing 0.4-0.6% of all malignancies in males in the U.S. and Europe. Early diagnosis is imperative, as lymphatic spread is associated with a dismal prognosis. The estimated 5-year survival rate in patients with pelvic lymph node involvement is 0%. Moreover, there are limited treatment options that carry significant toxicity risks. Accurate biomarkers to evaluate treatment response and guide treatment to improve outcomes are needed. Molecular residual disease monitoring with circulating tumor DNA (ctDNA) may be helpful in these scenarios. Methods: This is a retrospective analysis of a cohort of 7 patients with advanced HPV-unassociated penile SCC treated at Rush University Medical Center who monitored closely for molecular residual disease (MRD). Signatera (Natera Inc.), a personalized tumor-informed ctDNA assay, was utilized for detection and quantification of ctDNA in patients’ plasma samples, measured at regular intervals. Progression of disease was based on radiographic imaging. Results: In our cohort, personalized, tumor-informed ctDNA assays were designed for 100% (7/7) of the patients. ctDNA was detectable in at least one time point in all of the patients. One patient underwent partial penectomy and lymph node (LN) dissection with 1/11 LN involved. He is being monitored without adjuvant treatment and has sustained ctDNA clearance. Another patient underwent surgery, and had positive post-operative ctDNA. He was treated with adjuvant TIP (paclitaxel, ifosfamide, and cisplatin) with subsequent ctDNA clearance. In 3 of the patients, ctDNA was checked at regular intervals and rising ctDNA prompted imaging studies that showed progression. These patients proceeded to second line treatment options. The remaining 2 patients are non-surgical candidate with LN positivity, who will begin treatment with TIP and monitoring of ctDNA after each cycle of chemotherapy. Twenty-eight percent (2/7) of patients remain alive with sustained ctDNA clearance. Twenty-eight percent (2/7) of patients remain alive with ctDNA positivity, planned to initiate treatment and monitoring of ctDNA at regular intervals. Forty-three percent (3/7) of patients who had persistent ctDNA positivity are now deceased. Conclusions: Our data suggests that a personalized, tumor-informed ctDNA assay is not only useful for MRD monitoring, but also highly predictive of treatment response and imaging-based progression in patients with penile SCC. In our sample, MRD status correlated with both radiographic progression and clinical outcomes. Prospective studies are needed to better understand how ctDNA can be used to guide neoadjuvant and adjuvant approaches, including treatment intensification or de-escalation, in patients with penile SCC.

A Case of Penile Squamous Cell Carcinoma Treated with a Combination of Antiepidermal Growth Factor Receptor Antibody and Chemotherapy

Beyond chemotherapy for advanced disease-the role of EGFR and PD-1 inhibitors.

Beyond Chemotherapy for Advanced Disease—the Role of EGFR and PD-1 Inhibitors

Programmed Cell Death-1 Inhibitor Combination Treatment for Recurrent Proficient Mismatch Repair/ Miscrosatellite-Stable Type Endometrial Cancer: A Case Report.

Evidence for Efficacy of Treatment With the Anti-PD-1 Mab Nivolumab in Radiation and Multichemorefractory Advanced Penile Squamous Cell Carcinoma

Successful Outcome of Neoadjuvant PD-1 Blockade, VEGFR-2 Inhibitor Plus Chemotherapy for Potentially Unresectable Esophagogastric Junctional Squamous Cell Carcinoma: a Case Report

Immune checkpoint inhibitor plus anti-EGFR target therapy plus chemotherapy in patients with locally advanced penile squamous cell carcinoma.

Feasibility and Activity of Sorafenib and Sunitinib in Advanced Penile Cancer: A Preliminary Report

Case report: Pyrotinib in the treatment of advanced scrotal EMPD combined with sweat gland carcinoma

PD-1 inhibitor treatment in a penile cancer patient with MMR/MSI status heterogeneity: A case report

Resveratrol prevents TNFα-induced suppression of adiponectin expression via PPARγ activation in 3T3-L1 adipocytes

Neoadjuvant Docetaxel, Cisplatin and Ifosfamide (ITP) Combination Chemotherapy for Treating Penile Squamous Cell Carcinoma Patients with Terminal Lymph Node Metastasis

[Efficacy and Safety of Neoadjuvant Toripalimab Combined with Nimotuzumab and Chemotherapy in Patients with Unresectable Stage Ⅳ Squamous Cell Carcinoma of Penis].

Case report: A lung squamous cell carcinoma patient with a rare EGFR G719X mutation and high PD-L1 expression showed a good response to anti-PD1 therapy

Longitudinal circulating tumor DNA monitoring for detection of molecular residual disease in patients with penile squamous cell carcinoma.

[The pure preparation of globin of an invertebrate hemoglobin of Tubifex tubifex].

Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors

Complete Response to Immunotherapy Combined with Chemotherapy in a Patient with Gynecological Mixed Cancer Mainly Composed of Small Cell Neuroendocrine Carcinoma with High Tumor Mutational Burden: A Case Report

Camrelizumab combined with TIP (paclitaxel+cisplatin+ifosfamide) as neoadjuvant treatment of locally advanced penile cancer before lymphadenectomy: An exploratory, phase II study.

Dual Inhibition of Epidermal Growth Factor Receptor and Insulin-Like Growth Factor Receptor I: Reduction of Angiogenesis and Tumor Growth in Cutaneous Squamous Cell Carcinoma.

Therapeutic Targets in Advanced Penile Cancer: From Bench to Bedside